Fig. 4

Effective therapeutic windows for KW6002 to confer protection against OIR. a, c, e Pups were treated with KW6002 (10 mg/kg) in different developmental stages (P7–17, P7–12, and P12–17) and retinal vasculatures were analyzed by whole-mount isolectin B4 staining at P17 of OIR. Avascular areas are shown by red dotted line. Neovascularization tufts are indicated by purple line. Scale bar: 500 μm. b, d, f Schematic of the experimental design: KW6002 was administered by intraperitoneal injection at volume of 10 mg/kg at different postnatal developmental stages (P7 or P12) and for different period (P7-P17, P7-P12 or P12-P17) every other day. OIR mice were euthanized at P17. b, d, f Avascular area (%) was quantified as a percentage of the whole retinal surface (n = 7–9/group). The neovascularization tufts area (%) was quantified as a percentage of whole retinal area (n = 7–9/group). ***p < 0.001, *p < 0.05, Student’s t-test or Mann-Whitney U test, n = 7–9/group